Gross Profit Trends Compared: Takeda Pharmaceutical Company Limited vs Amneal Pharmaceuticals, Inc.

Comparing Gross Profit Trends of Takeda vs Amneal

__timestampAmneal Pharmaceuticals, Inc.Takeda Pharmaceutical Company Limited
Wednesday, January 1, 20144496340001256834000000
Thursday, January 1, 20154992260001271973000000
Friday, January 1, 20165974550001173296000000
Sunday, January 1, 20175261780001274610000000
Monday, January 1, 20187164030001437534000000
Tuesday, January 1, 20193529970002201424000000
Wednesday, January 1, 20206283930002203504000000
Friday, January 1, 20217689730002462160000000
Saturday, January 1, 20227847080002783406000000
Sunday, January 1, 20238205650002832257000000
Monday, January 1, 20242832257000000
Loading chart...

Cracking the code

Gross Profit Trends: A Tale of Two Pharmaceutical Giants

In the ever-evolving pharmaceutical industry, understanding financial trends is crucial. This analysis compares the gross profit trajectories of Takeda Pharmaceutical Company Limited and Amneal Pharmaceuticals, Inc. from 2014 to 2023. Takeda, a Japanese titan, consistently outperformed with a staggering 1,000-fold higher gross profit than Amneal, a U.S.-based company. Notably, Takeda's gross profit surged by approximately 125% from 2014 to 2023, peaking at 2.83 trillion in 2023. Meanwhile, Amneal's growth was more modest, with a 82% increase over the same period, reaching 820 million in 2023. The data highlights Takeda's robust market position and strategic growth, while Amneal's steady rise reflects its resilience in a competitive landscape. Missing data for Amneal in 2024 suggests potential challenges or reporting delays. These insights underscore the dynamic nature of the pharmaceutical sector and the importance of strategic financial planning.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025